The NAG-1 expression levels substantially increase in cancer cells, serum, and/or cerebrospinal fluid during the progression of diverse human aggressive cancers, such as intracranial brain tumors, melanoma, gastrointestinal, pancreatic, colorectal, prostate, breast, and lung epithelial cancers. Here, GDF15 is linked to melanoma.